ACADIA PHARMACEUTICALS A/S: Financial statements 2022
CVR: 19670694
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
ACADIA PHARMACEUTICALS A/S (CVR 19670694) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -253,519 and a net result of DKK -253,577 compared with DKK -21,200 the year before. Equity in the 2022 report amounted to DKK -841,377.
- Gross Profit
- DKK -253,519
- Profit/Loss
- DKK -253,577
- Equity
- DKK -841,377
- Total Assets
- DKK 4,894
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | -254K | -254K | -841K | 0 |
| 2021 | - | -21K | -21K | -588K | 0 |
| 2020 | - | - | -57K | -567K | 0 |
| 2019 | - | - | -75K | -510K | 0 |
| 2018 | - | - | -47K | -435K | 0 |
Official annual report
Keep an eye on ACADIA PHARMACEUTICALS A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
ACADIA PHARMACEUTICALS A/S has published its annual report for 2021. Gross profit came to DKK -21,167, and the net result was DKK -21,200.
As of July 6, 2022, James Kenji Kihara has joined the board of directors of ACADIA PHARMACEUTICALS A/S.
As of July 6, 2022, Elena Heather Ridloff has left the board of directors of ACADIA PHARMACEUTICALS A/S.
About ACADIA PHARMACEUTICALS A/S
ACADIA PHARMACEUTICALS A/S is a Danish company of the type Aktieselskab based in Bagsværd, founded in 1996. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named RECEPTOR TECHNOLOGIES A/S and VICH 4861 A/S. The management consists of Jennifer Jane Rhodes. The board consists of Martin Choy (chair), James Kenji Kihara, Jennifer Jane Rhodes and Peter Francis Chae. The company is owned by Acadia Pharmaceuticals Inc.. The company has 6 employees (2005). In 2025, the company reported a net result of DKK -471,043 compared with DKK -99,365 the year before. Equity in the 2025 report amounted to DKK -1,563,180.